Knights of Columbus Asset Advisors LLC Buys 25 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Knights of Columbus Asset Advisors LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,234 shares of the medical research company’s stock after purchasing an additional 25 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Thermo Fisher Scientific were worth $705,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Patten & Patten Inc. TN raised its stake in Thermo Fisher Scientific by 3.1% in the 3rd quarter. Patten & Patten Inc. TN now owns 573 shares of the medical research company’s stock worth $327,000 after acquiring an additional 17 shares during the last quarter. Harvest Investment Services LLC raised its stake in Thermo Fisher Scientific by 1.2% in the 3rd quarter. Harvest Investment Services LLC now owns 1,392 shares of the medical research company’s stock worth $795,000 after acquiring an additional 17 shares during the last quarter. Cutter & CO Brokerage Inc. raised its stake in Thermo Fisher Scientific by 3.8% in the 3rd quarter. Cutter & CO Brokerage Inc. now owns 470 shares of the medical research company’s stock worth $269,000 after acquiring an additional 17 shares during the last quarter. AlphaMark Advisors LLC raised its stake in Thermo Fisher Scientific by 0.6% in the 3rd quarter. AlphaMark Advisors LLC now owns 2,956 shares of the medical research company’s stock worth $1,689,000 after acquiring an additional 17 shares during the last quarter. Finally, Bogart Wealth LLC raised its stake in Thermo Fisher Scientific by 11.6% in the 3rd quarter. Bogart Wealth LLC now owns 173 shares of the medical research company’s stock worth $99,000 after acquiring an additional 18 shares during the last quarter. 85.93% of the stock is owned by institutional investors and hedge funds.

In other news, COO Mark Stevenson sold 26,925 shares of the business’s stock in a transaction that occurred on Monday, November 1st. The stock was sold at an average price of $632.69, for a total transaction of $17,035,178.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Stephen Williamson sold 22,550 shares of the business’s stock in a transaction that occurred on Tuesday, November 2nd. The stock was sold at an average price of $638.10, for a total value of $14,389,155.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 76,400 shares of company stock worth $48,437,702. 0.44% of the stock is currently owned by insiders.

A number of equities analysts recently issued reports on the company. Citigroup raised their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Thursday, October 28th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, September 20th. KeyCorp lifted their price objective on Thermo Fisher Scientific from $555.00 to $710.00 and gave the company an “overweight” rating in a research note on Monday, September 20th. Morgan Stanley started coverage on Thermo Fisher Scientific in a research note on Thursday, October 28th. They set an “overweight” rating for the company. Finally, Cowen lifted their price objective on Thermo Fisher Scientific from $655.00 to $696.00 and gave the company an “outperform” rating in a research note on Thursday, October 14th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $635.78.

TMO stock opened at $594.80 on Friday. The company has a current ratio of 3.19, a quick ratio of 2.56 and a debt-to-equity ratio of 0.56. Thermo Fisher Scientific Inc. has a 12-month low of $433.52 and a 12-month high of $672.34. The stock has a market cap of $234.38 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 1.98 and a beta of 0.74. The business’s 50-day moving average is $636.31 and its 200 day moving average is $587.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 27th. The medical research company reported $5.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.67 by $1.09. Thermo Fisher Scientific had a return on equity of 28.14% and a net margin of 21.93%. The company had revenue of $9.33 billion for the quarter, compared to analysts’ expectations of $8.41 billion. During the same period in the previous year, the firm posted $5.63 EPS. Thermo Fisher Scientific’s revenue was up 9.5% compared to the same quarter last year. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.76 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Thursday, September 23rd that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 1.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 14th. Investors of record on Wednesday, December 15th were issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.17%. The ex-dividend date was Tuesday, December 14th. Thermo Fisher Scientific’s payout ratio is 4.83%.

About Thermo Fisher Scientific

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

See Also: Using other technical indicators with support levels

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.